Xtant delivers positive net income, adjusted EBITDA and operating cash flow Exhibit 99.1 Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture BELGRADE, Mont., March 31, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused ...